• Underscores Company’s preparation for potential NDA submission for SB206 in molluscum
  • Role to lead cross-functional coordination of key activities and timelines for the program
  • SB206 top line results are expected no later than early in the first quarter of 2020

MORRISVILLE, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced the appointment of Michelle Patterson as Vice President of Project Management.

In this centrally positioned role, Ms. Patterson will manage the delivery of key product portfolio milestones by integrating work activity across Novan’s business functions including regulatory, pre-clinical, clinical, manufacturing and CMC. Ms. Patterson will lead the cross-functional coordination and orchestration of integrated project plans for the SB206 New Drug Application (“NDA”) submission, should the Phase 3 clinical program in molluscum contagiosum be positive. The role will report to Paula Brown Stafford in order to ensure alignment and coordination across functions.

“Michelle is a highly-qualified and widely recognized industry leader who will have an immediate and positive impact on our Company,” commented Paula Brown Stafford, President and Chief Operating Officer of Novan. Ms. Stafford further commented, “With Phase 3 molluscum pivotal trials well underway and results expected no later than early in the first quarter of 2020, Michelle will add tremendous value to our process, approach and project management mindset in order to be prepared for a potential NDA submission. We are lucky to bring her back to Novan and our team is thrilled to have her returning.”

Ms. Patterson brings nearly 20 years of industry project management experience to Novan. Most recently, she served as Senior Director of Program Management with Urovant Sciences. Prior to joining Urovant Sciences, Ms. Patterson served in senior project management roles at Roivant Sciences, Novan, GlaxoSmithKline, BioCryst Pharmaceuticals and Eli Lilly.

About Novan

Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases with significant unmet needs. We believe that our ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to improve patient outcomes in a variety of dermatological, women’s health and gastrointestinal diseases.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates and the future prospects of our business and our product candidates. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, risks and uncertainties in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, potential for delays and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research activities or additional trials; risks related to the regulatory approval process, which is lengthy, time-consuming and inherently unpredictable, including the risk that our product candidates may not be approved or that additional studies may be required for approval or other delays may occur and that we may not obtain funding sufficient to complete the regulatory or development process; our ability to obtain additional funding or enter into strategic relationships or other business development necessary for the further development or commercialization of our product candidates; and other risks and uncertainties described in our annual report filed with the SEC on Form 10-K for the twelve months ended December 31, 2018, and in our subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.


(Investors & Media)
Cole Ikkala
Director, Investor Relations, Communications & Business Development